1,946 reports of this reaction
1.2% of all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE reports
#20 most reported adverse reaction
ECONOMIC PROBLEM is the #20 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc. There are 1,946 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE to ECONOMIC PROBLEM. This represents approximately 1.2% of all 167,978 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE who experience economic problem should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ECONOMIC PROBLEM is a less commonly reported adverse event for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, but still significant enough to appear in the safety profile.
In addition to economic problem, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to economic problem in FDA adverse event reports:
ECONOMIC PROBLEM has been reported as an adverse event in 1,946 FDA reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ECONOMIC PROBLEM accounts for approximately 1.2% of all adverse event reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience economic problem while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.